Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
759.490.18%
QQQ
708.370.11%
BTC/USD
76159.982.5991%
DIA
521.890.49%
GLD
393.440.15%
TLT
80.650.35%

Apyx Medical Corp

APYXNASDAQ
Trade with Public
Trade with Public
$3.10
0.082.65%
Last update: Sep 15, 7:08 AM
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Apyx Medical Analyst Price Targets

Wall Street analyst price targets and consensus rating for Apyx Medical (APYX).

Price Target Range — 4 Quarters

Analyst Consensus — 7 Analysts

1S.Buy
5Buy
1Hold
Consensus RatingBuy# Analysts7Avg. Consensus PT$6Upside to Avg. PT+104.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 13, 2026HC Wainwright & Co.Yi ChenInitiateBuy$7
Mar 11, 2026Craig-HallumMatthew HewittPT RaiseBuy$5→$6
More with Benzinga EdgeGet Access

Analyst Ratings News

This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Wall Street analysts changed outlook on top stocks. To see all changes, visit the analyst ratings page. FAST stock has a Buy rating with $55 PT.
Avi Kapoor

PRO
HC Wainwright & Co. Initiates Coverage On Apyx Medical with Buy Rating, Announces Price Target of $7

HC Wainwright & Co. analyst Yi Chen initiates coverage on Apyx Medical (NASDAQ:APYX) with a Buy rating and announces Price Target of $7.
Benzinga Newsdesk

PRO
Craig-Hallum Maintains Buy on Apyx Medical, Raises Price Target to $6

Craig-Hallum analyst Matthew Hewitt maintains Apyx Medical (NASDAQ:APYX) with a Buy and raises the price target from $5 to $6.
Benzinga Newsdesk

This JM Smucker Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday

Wall Street analysts upgraded Uniqure NV, Apyx Medical Inc, J M Smucker Co, and VTEX with raised price targets. See analyst ratings page.
Avi Kapoor

PRO
BTIG Upgrades Apyx Medical to Buy, Announces $6 Price Target

BTIG analyst Sam Eiber upgrades Apyx Medical (NASDAQ:APYX) from Neutral to Buy and announces $6 price target.
Benzinga Newsdesk

PRO
Roth Capital Initiates Coverage On Apyx Medical with Buy Rating, Announces Price Target of $6

Roth Capital analyst Kyle Bauser initiates coverage on Apyx Medical (NASDAQ:APYX) with a Buy rating and announces Price Target of $6.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved